The University of Southampton
University of Southampton Institutional Repository

Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: Outcomes of a systematic review and meta-analysis

Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: Outcomes of a systematic review and meta-analysis
Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: Outcomes of a systematic review and meta-analysis

Objective: We aimed to assess the safety of topical non-steroidal anti-inflammatory drugs (NSAIDs) in the management of osteoarthritis (OA) in a systematic review and meta-analysis of randomized, placebo-controlled trials. Methods: A comprehensive literature search was undertaken in the MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus electronic databases. Randomized, double-blind, placebo-controlled, parallel-group trials that assessed adverse events (AEs) with topical NSAIDs in patients with OA were eligible for inclusion. Authors and/or study sponsors were contacted to obtain the full report of AEs. The primary outcomes were overall severe and serious AEs, as well as the following MedDRA System Organ Class (SOC)-related AEs: gastrointestinal, vascular, cardiac, nervous system, skin and subcutaneous tissue, musculoskeletal and connective tissue. Results: The search strategy identified 1209 records, from which 25 papers were included in the qualitative synthesis and 19 were included in the meta-analysis, after exclusions. Overall, more total AEs (odds ratio [OR] 1.16, 95% confidence interval [CI] 1.04–1.29; I 2  = 0.0%) and more withdrawals due to AEs (OR 1.49, 95% CI 1.15–1.92; I 2  = 0.0%) were observed with topical NSAIDs compared with placebo. The same results were achieved with topical diclofenac, largely driven by an increase in skin and subcutaneous tissue disorders (OR 1.73, 95% CI 0.96–3.10), although the difference was not statistically significant compared with placebo. No significant difference in the odds for gastrointestinal disorders was observed between topical NSAIDs and placebo (OR 0.96, 95% CI 0.73–1.27). Conclusions: Topical NSAIDs may be considered safe in the management of OA, especially with regard to low gastrointestinal toxicity. The use of topical NSAIDs in OA should be considered, taking into account their risk: benefit profile in comparison with other anti-OA treatments.

1170-229X
45-64
Honvo, Germain
b028bd1a-b0a7-444f-bde5-32b5b611b9af
Leclercq, Victoria
3005c594-3800-47bb-a4d1-6cac8ace94b4
Geerinck, Anton
06bb9a12-8354-4567-814f-743a14a6b881
Thomas, Thierry
9d1f93b4-bdfd-48a9-ad06-03fe38e01a74
Veronese, Nicola
a9a97f63-a828-45a3-bae0-68182c5a44fd
Charles, Alexia
00074b06-5e9c-4793-a3b4-243ae6d2405a
Rabenda, Véronique
cc81b2c5-82bc-490a-ae8b-94d251b7b5ed
Beaudart, Charlotte
bdc9da98-791a-474b-9745-be0695a4d8a9
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Reginster, Jean Yves
08b05e27-73dd-4ce9-90e5-d64ec922147a
Bruyère, Olivier
ba727e54-ca17-4fa8-be3d-4729fb4b8c0d
Honvo, Germain
b028bd1a-b0a7-444f-bde5-32b5b611b9af
Leclercq, Victoria
3005c594-3800-47bb-a4d1-6cac8ace94b4
Geerinck, Anton
06bb9a12-8354-4567-814f-743a14a6b881
Thomas, Thierry
9d1f93b4-bdfd-48a9-ad06-03fe38e01a74
Veronese, Nicola
a9a97f63-a828-45a3-bae0-68182c5a44fd
Charles, Alexia
00074b06-5e9c-4793-a3b4-243ae6d2405a
Rabenda, Véronique
cc81b2c5-82bc-490a-ae8b-94d251b7b5ed
Beaudart, Charlotte
bdc9da98-791a-474b-9745-be0695a4d8a9
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Reginster, Jean Yves
08b05e27-73dd-4ce9-90e5-d64ec922147a
Bruyère, Olivier
ba727e54-ca17-4fa8-be3d-4729fb4b8c0d

Honvo, Germain, Leclercq, Victoria, Geerinck, Anton, Thomas, Thierry, Veronese, Nicola, Charles, Alexia, Rabenda, Véronique, Beaudart, Charlotte, Cooper, Cyrus, Reginster, Jean Yves and Bruyère, Olivier (2019) Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: Outcomes of a systematic review and meta-analysis. Drugs and Aging, 36 (Supplement 1), 45-64. (doi:10.1007/s40266-019-00661-0).

Record type: Review

Abstract

Objective: We aimed to assess the safety of topical non-steroidal anti-inflammatory drugs (NSAIDs) in the management of osteoarthritis (OA) in a systematic review and meta-analysis of randomized, placebo-controlled trials. Methods: A comprehensive literature search was undertaken in the MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus electronic databases. Randomized, double-blind, placebo-controlled, parallel-group trials that assessed adverse events (AEs) with topical NSAIDs in patients with OA were eligible for inclusion. Authors and/or study sponsors were contacted to obtain the full report of AEs. The primary outcomes were overall severe and serious AEs, as well as the following MedDRA System Organ Class (SOC)-related AEs: gastrointestinal, vascular, cardiac, nervous system, skin and subcutaneous tissue, musculoskeletal and connective tissue. Results: The search strategy identified 1209 records, from which 25 papers were included in the qualitative synthesis and 19 were included in the meta-analysis, after exclusions. Overall, more total AEs (odds ratio [OR] 1.16, 95% confidence interval [CI] 1.04–1.29; I 2  = 0.0%) and more withdrawals due to AEs (OR 1.49, 95% CI 1.15–1.92; I 2  = 0.0%) were observed with topical NSAIDs compared with placebo. The same results were achieved with topical diclofenac, largely driven by an increase in skin and subcutaneous tissue disorders (OR 1.73, 95% CI 0.96–3.10), although the difference was not statistically significant compared with placebo. No significant difference in the odds for gastrointestinal disorders was observed between topical NSAIDs and placebo (OR 0.96, 95% CI 0.73–1.27). Conclusions: Topical NSAIDs may be considered safe in the management of OA, especially with regard to low gastrointestinal toxicity. The use of topical NSAIDs in OA should be considered, taking into account their risk: benefit profile in comparison with other anti-OA treatments.

Text
Honvo2019_Article_SafetyOfTopicalNon-steroidalAn - Version of Record
Available under License Creative Commons Attribution.
Download (1MB)

More information

e-pub ahead of print date: 9 May 2019

Identifiers

Local EPrints ID: 431437
URI: http://eprints.soton.ac.uk/id/eprint/431437
ISSN: 1170-229X
PURE UUID: 28fc4824-804a-40d2-a19a-34917f10e55a
ORCID for Cyrus Cooper: ORCID iD orcid.org/0000-0003-3510-0709

Catalogue record

Date deposited: 03 Jun 2019 16:30
Last modified: 18 Mar 2024 02:46

Export record

Altmetrics

Contributors

Author: Germain Honvo
Author: Victoria Leclercq
Author: Anton Geerinck
Author: Thierry Thomas
Author: Nicola Veronese
Author: Alexia Charles
Author: Véronique Rabenda
Author: Charlotte Beaudart
Author: Cyrus Cooper ORCID iD
Author: Jean Yves Reginster
Author: Olivier Bruyère

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×